Geron Corp

GERNNASDAQ · USD
0.92USD-0.07 (-7.41%)
415

Geron Corp (GERN) Covered Calls

Geron Corp trades in the Biotechnology industry with an IV Rank of 34.13%, average versus the past year. GERN's highest covered call setup is the $1.50 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 50.00% out of the money with 430 days to expiration, a 75.00% return until expiration, and a 63.66% theoretical annualized return. Across the setups shown, annualized returns run from 16.98% to 63.66% at strikes between $1.00 and $1.50, with 31 to 430 days to expiration, as of Nov 17, 2026.

Read more

Running GERN covered calls helps you generate income from Geron Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GERN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If GERN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GERN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GERN covered call is worth writing.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

2028-01-214301.5050.000.250.5075.0075.0063.66-25.00+0.632750.25
2027-01-15591.000.000.100.7510.0010.0061.86-10.00+0.711,9050.65
2026-12-18311.000.000.050.205.005.0058.87-5.00+0.573840.15
2027-03-191221.000.000.150.3015.0015.0044.88-15.00+0.621,3540.15
2027-06-172121.000.000.200.6020.0020.0034.43-20.00+0.70490.40
2028-01-214301.000.000.200.6520.0020.0016.98-20.00+0.721,1500.45

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank34.13% Moderate
  • Market cap (M$)638
  • 52 weeks high-50.75%
  • 52 weeks low17.86%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$3.50
    281.47% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-04
  • P/E—
  • Future P/E11.66
  • EPS (ttm)-0.07
  • EPS growth next 5 years—

As of Nov 18, 2026